miR-101 Acts as a Tumor Suppressor by Targeting Kruppel-like Factor 6 in Glioblastoma Stem Cells

CNS Neuroscience and Therapeutics

Volumn 21, Issue 1, 2015, Pages 40-51

  Yao, Yi Long ^a   Ma, Jun ^a   Wang, Ping ^a   Xue, Yi Xue ^a   Li, Zhen ^a   Zhao, Li Ni ^a   Li, Zhi Qing ^a   Feng, Tian Da ^a   Liu, Yun Hui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CHI3L1; Glioblastoma stem cells; KLF6; MicroRNAs; Mir 101

Indexed keywords

BETA TUBULIN; CD133 ANTIGEN; CHITINASE; CHITINASE 3 LIKE PROTEIN 1; KRUPPEL LIKE FACTOR 6; MICRORNA 101; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NESTIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; KLF6 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; LECTIN; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MICRORNA; MIRN101 MICRORNA, HUMAN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GLIOBLASTOMA; GLIOBLASTOMA STEM CELL; HUMAN; HUMAN TISSUE; LUCIFERASE ASSAY; MOUSE; NEURAL STEM CELL; NONHUMAN; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL MOTION; GENETICS; HEK293 CELL LINE; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR INVASION;

ADIPOKINES; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; GLIOBLASTOMA; HEK293 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LECTINS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE, NEUROLOGIC MUTANTS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 84918540870     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12321     Document Type: Article

References (57)

1. Bartek J Jr, Ng K, Bartek J, Fischer W, Carter B, Chen CC. Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry 2012;83:753-760.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7021.
4. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
5. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.
6. Mazzoleni S, Politi LS, Pala M, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010;70:7500-7513.
7. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
8. Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-526.
9. Gilbert CA, Ross AH. Cancer stem cells: Cell culture, markers, and targets for new therapies. J Cell Biochem 2009;108:1031-1038.
10. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
11. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
12. Medina PP, Slack FJ. microRNAs and cancer: An overview. Cell Cycle 2008;7:2485-2492.
13. Gangaraju VK, Lin H. MicroRNAs: Key regulators of stem cells. Nat Rev Mol Cell Biol 2009;10:116-125.
14. Ventura A, Jacks T. MicroRNAs and cancer: Short RNAs go a long way. Cell 2009;136:586-591.
15. Smits M, Nilsson J, Mir SE, et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010;1:710-720.
16. Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010;9:108.
17. Semaan A, Qazi AM, Seward S, et al. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharm Res 2011;28:3079-3090.
18. Wang HJ, Ruan HJ, He XJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 2010;46:2295-2303.
19. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 2010;42:363-369.
20. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009;69:1135-1142.
21. Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 2012;586:4362-4370.
22. Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. Int J Mol Sci 2013;14:14712-14723.
23. Lu L, Tang D, Wang L, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways. Acta Pharmacol Sin 2012;33:531-541.
24. Strillacci A, Griffoni C, Sansone P, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009;315:1439-1447.
25. Buechner J, Tomte E, Haug BH, et al. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011;105:296-303.
26. Li K, Liu C, Zhou B, et al. Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP Cells. Int J Mol Sci 2013;14:11981-11993.
27. Visani M, de Biase D, Marucci G, et al. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol 2014;8:417-430.
28. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
29. Ma J, Wang P, Liu Y, Zhao L, Li Z, Xue Y. Kruppel-Like Factor 4 Regulates Blood-Tumor Barrier Permeability via ZO-1, Occludin and Claudin-5. J Cell Physiol 2014;229:916-926.
30. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-1577.
31. Zhao X, Monson C, Gao C, et al. Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. Dev Biol 2010;344:79-93.
32. Guo W, Keckesova Z, Donaher JL, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015-1028.
33. Nagata S, Hirano K, Kanemori M, Sun LT, Tada T. Self-renewal and pluripotency acquired through somatic reprogramming to human cancer stem cells. PLoS ONE 2012;7:e48699.
34. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010;12:49-57.
35. Kojima S, Hayashi S, Shimokado K, et al. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. Blood 2000;95:1309-1316.
36. Warke VG, Nambiar MP, Krishnan S, et al. Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 2003;278:14812-14819.
37. Hu Z, Lin Y, Chen H, et al. MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun 2013;435:82-87.
38. Cho HM, Jeon HS, Lee SY, et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med 2011;2:963-967.
39. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-160.
40. Bieker JJ. Kruppel-like factors: Three fingers in many pies. J Biol Chem 2001;276:34355-34358.
41. Tchirkov A, Sapin V, Marceau G, et al. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem Lab Med 2010;48:1167-1170.
42. Xia H, Zhang W, Li Y, Guo N, Yu C. EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro. Biomed Res Int 2014;2014:348728.
43. Sirach E, Bureau C, Peron JM, et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ 2007;14:1202-1210.
44. Wang L, Zhang X, Jia LT, et al. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2014;59:1850-1863.
45. Strillacci A, Valerii MC, Sansone P, et al. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol 2013;229:379-389.
46. Sangodkar J, Shi J, DiFeo A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer 2009;45:666-676.
47. Henrissat B, Bairoch A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem J 1993;293(Pt 3):781-788.
48. Ku BM, Lee YK, Ryu J, et al. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 2011;128:1316-1326.
49. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005;11:2258-2264.
50. Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479-501.
51. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173.
52. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005;11:3326-3334.
53. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456-4468.
54. Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332-15343.
55. Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010;127:1081-1095.
56. Inoue T, Meyer T. Synthetic activation of endogenous PI3K and Rac identifies an AND-gate switch for cell polarization and migration. PLoS ONE 2008;3:e3068.
57. Tang H, Sun Y, Shi Z, et al. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-kappaB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol 2013;190:438-446.